BioHedge Weekly
13D/13G filings from 17 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform with clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Delivery
Get next week's BioHedge Weekly by email
One email per week. We follow up on coverage that's relevant to you.
or email [email protected]
Weekly Filing Volume
Filings This Week
| Fund / Company | Ownership & Type |
|---|---|
Perceptive Advisors TRINITY BIOTECH (TRIB) | 9.9% 13D/A [SEC] |
Perceptive Advisors SAB BIOTHERAPEUTICS INC (SABS) | 7.3% New 13G [SEC] |
Fairmount Funds Management LLC Cogent Biosciences, Inc. (COGT) | 9.9% 13D/A [SEC] |
Fairmount Funds Management LLC Apogee Therapeutics, Inc. (APGE) | 10.0% 13D/A [SEC] |
New Positions
Funds disclosing more than 5% ownership in a company for the first time.
| Fund / Company | Ownership & Type |
|---|---|
Perceptive Advisors SAB BIOTHERAPEUTICS INC (SABS) | 7.3% SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses more than 5% ownership in a company for the first time.
We track 17 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.